Pindolol
As of the edition of 20 October 2026, Pindolol is a small molecule: marketed, first approved in 1978 (CA); acts on ADRB1 and ADRB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Visken
- First approved
- 31 December 1978 (CA)
- Approvals on record
- 7 in 3 regions
- Holder of the most recent approval
- Novartis; 3 holders in all
- Registered trials
- 8, 2 stopped early
- Disease areas
- Mental health; Chemically induced; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 3 | 2 | 1 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Applicant | 1982 to now |